Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0023890 (cirrhosis)
 42,195 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

To elucidate the cell biological significance of ras oncogene, the expression of ras-p21 was analyzed in 53 cases of liver tissues including 34 cases of hepatocellular carcinoma (HCC), by using immunohistochemical method. In result, 22 (65%) cases of 34 HCC and 34 (79%) cases of 43 liver cirrhosis were positive for p21, whereas all of chronic hepatitis and normal livers were negative. Especially, comparative study between the expression of p21 and clinicopathological background of HCC revealed that p21 was prominently expressed in well differentiated form, nodular type, small liver cancer, and the cases showing AFP levels below 400 ng/ml. From these results, it was indicated that ras oncogene might play an important role in malignant transformation of hepatocytes or differentiation of HCC.
 ...
PMID:[The expression of ras p21 product in hepatocellular carcinoma]. 170 Jan 76

The serum levels of tumour marker CA 125 were measured in 162 patients with various digestive tract malignancies and in 155 patients with benign digestive tract diseases. The highest frequency of elevated CA 125 values (greater than 35 U ml-1) was found in patients with liver cancer (78%), but the level was equally often elevated in liver cirrhosis (78%). Two-thirds of the patients with biliary tract cancer had an increased CA 125 concentration, while four patients with benign biliary diseases had an elevated value. The serum level of CA 125 was elevated in only 20% of 60 patients with primary colorectal cancer, and in none of those with local disease (Dukes A or B). The CA 125 concentration seldom increased in patients with recurrent colorectal carcinoma. Twenty-three per cent of 44 patients with gastric cancer had an elevated CA 125 value. Two of 33 patients with benign colorectal and one of 68 patients with benign gastric diseases had an increased CA 125 concentration. The serum values of CA 125 showed no correlation with those of tumour markers alphafetoprotein (AFP), carcinoembryonic antigen (CEA) or CA 19-9. AFP was superior to the other markers in the diagnosis of liver diseases, while CA 19-9 showed the greatest accuracy in gastric diseases. In colorectal diseases, CEA had a higher sensitivity, but a lower specificity than CA 125 and CA 19-9. CA 125 and CA 19-9 had similar sensitivities for biliary tract cancer.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:Tumour marker CA 125 in patients with digestive tract malignancies. 171 1

Des-gamma-carboxy prothrombin (DCP) was evaluated as a serological marker for hepatocellular carcinoma (HCC), particularly in patients with early HCC. In 1192 patients with various diseases, plasma DCP levels were measured by a newly developed enzyme immunoassay method using an anti-DCP monoclonal antibody. Of the 254 patients with HCC, 143 (56%) had abnormal DCP levels of greater than 0.1 AU/ml. In contrast, elevated DCP levels were rarely observed in patients with chronic hepatitis, liver cirrhosis, metastatic liver cancer, and other malignant tumors. Because no correlation was observed between DCP and alpha-fetoprotein (AFP), the combined measurement of these two complementary markers appears to be useful in the diagnosis of HCC. Since normal levels were observed in 29 of 30 patients (97%) with small liver tumors measuring 2 cm or less in diameter, the diagnostic application of the DCP assay to small liver tumors is limited. However, in patients with tumors larger than 2 cm, the plasma DCP assay may even be more useful than AFP. Among 46 patients with liver cirrhosis or chronic hepatitis who subsequently developed HCC, significantly increased DCP and AFP levels were observed in nine patients (20%) and 14 patients (30%), respectively, when a tumor was detected. When the results of both assays were combined, 19 patients (41%) had elevated levels of one or both markers. Although the plasma DCP assay alone is not sensitive enough to detect early small liver cancers, it could be applied as a complementary tumor marker together with AFP.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:Clinical usefulness of des-gamma-carboxy prothrombin assay in early diagnosis of hepatocellular carcinoma. 172 Oct 19

Alpha-fetoprotein (AFP) was detected, by Ouchterlony immunodiffusion technique, in 81.5% of patients with histologically confirmed diagnosis of hepatocellular carcinoma. The test gave negative results with 35 cases of acute viral hepatitis, 7 haemochromatosis, 6 micronodular cirrhosis and 2 cholangiocellular carcinoma. Curiously, one patient with postnecrotic cirrhosis, a well recognized sequela of viral hepatitis, whose liver cell regeneration also showed "atypical changes", was AFP positive. AFP was not detected in sera from the general population which comprised 1029 male blood donors, 144 antenatal and 106 maternity cases. The only exception was the case of a woman who aborted a 5-month old foetus. A follow-up serum sample taken 3 months later was, however, negative for AFP. The frequency of hepatitis B surface antigen (HBsAg) detection in patients with hepatocellular carcinoma (25.9%) was 4 to 5 times higher than that in the general population. This strong association between HBsAg and primary liver cancer in countries where liver tumours are often AFP secretors suggests a role for hepatitis B virus, not only in the aetiology of the cancer, but also in the reactivation of the gene encoding this foetal protein.
 ...
PMID:A study of alpha-fetoprotein in primary liver cancer in Tanzania. 172 52

The interferons (IFN) act too slowly to arrest acute viral infections, but interferon-alpha (IFN alpha) preparations have proved useful in some chronic infections and will clearly be used increasingly in these in the future. In the preparations derived from human leucocytes or cultured B lymphoblastoid cells, which are in routine clinical use, mixtures of a number of distinct subtypes of human IFN alpha have been identified. There are also 3 slightly different versions of the same single subtype, IFN alpha-2, made by recombinant DNA procedures in bacteria. IFN alpha preparations are injected intramuscularly or subcutaneously. Dose-related side effects are common but usually tolerable, but prolonged treatment may cause increasing fatigue and depression. Some patients form neutralising antibodies which block the effects of the IFN; these appear to be relatively more common after recombinant IFN alpha-2 than after IFN derived from human cells. Given intranasally, IFN alpha can prevent a subsequent experimental rhinovirus infection, or the spread of natural colds within a family. Repeated administration progressively damages the nasal mucosa, so that long term prophylaxis is not possible. IFN alpha has proved useful in patients with papillomavirus warts of the larynx, ano-genital region (condyloma acuminata) and skin (common warts). Treatment regimens remain to be optimised and are likely to include surgery or other treatments. IFN alpha and zidovudine (azidothymidine) synergistically inhibit the growth of HIV in vitro, and combination are on trial in patients with early AIDS. Very large doses of IFN alpha are effective against Kaposi's sarcoma in some AIDS patients. In chronic hepatitis B, continuing virus replication may lead to cirrhosis or primary liver cancer. Earlier clinical trials with IFN alpha gave inconclusive results, but recent large studies have confirmed that 25 to 40% of patients obtain benefit; this probably results from both the antiviral and the immunomodulatory effects of IFN alpha. In patients with chronic hepatitis C, the biochemical markers usually improve rapidly during IFN alpha administration, but relapse if treatment is stopped after only a few months; to increase the chances of sustained cure, the treatment period is now being prolonged.
 ...
PMID:The use of interferon-alpha in virus infections. 172 72

We have evaluated tumor-associated trypsin inhibitor (TATI) as a marker for pancreatic and hepatic cancer. Of the patients studied 52 had pancreatic cancer, 30 primary liver cancer, 32 chronic pancreatitis, 25 biliary tract inflammatory disease, and 28 liver cirrhosis. A considerable number of falsely elevated values were observed in benign biliary diseases and in chronic relapsing pancreatitis. In pancreatic cancer the sensitivity of TATI was 63% while that of CEA was 40% and of CA19-9 77%. TATI is a marker of pancreatic disease but it does not differentiate between pancreatitis and pancreatic cancer. In liver cancer TATI and AFP has similar sensitivity and specificity.
 ...
PMID:Tumor-associated trypsin inhibitor in pancreatic diseases. 172 34

Using figures from the official death registry, we studied the descriptive epidemiology of primary liver cancer (PLC) in Italy from 1969 to 1985. The annual age-standardized mortality rate rose from 3.7/100,000 in 1969 to 4.7/100,000 in 1985, reaching the peak of 6.5/100,000 in 1983. The male/female ratio increased from 1.2:1 in 1969 to 2:1 in 1985. The age-specific mortality rate was very low in subjects under 55 years of age and peaked in subjects in their seventies and eighties. The rate was higher for men in all age-groups. The highest proportion of deaths (32%) was observed in the 65-74 year age group. The median age of death for patients with PLC was 10 years older than the median age for patients who died of alcoholic liver cirrhosis, but similar to that of patients who died of liver cirrhosis due to other causes. The highest regional age-standardized mortality rate was reported in Lombardia, Lazio and Veneto respectively, where hepatitis B virus (HBV) infection is less endemic than in the southern regions and the Islands. It should be kept in mind that these findings are not extremely accurate because they are based on mortality figures, where the contamination with metastatic cases is practically unavoidable; furthermore, their validity and comparability are not first-rate due to the wide variation in diagnostic accuracy and registration completeness.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:The descriptive epidemiology of primary liver cancer in Italy. 174 44

The polymerase chain reaction was used to search for hepatitis B virus (HBV)-DNA sequences in the sera of HBsAg-negative Senegalese patients suffering from liver cirrhosis or liver cancer. Amplified HBV-DNA sequences were detected by hybridization with a digoxigenin-labelled HBV-DNA probe. HBV-DNA was detected in 17% of HBsAg negative Senegalese subjects from the general population and in 44% and 58% of the patients suffering from cirrhosis or primary hepatocellular carcinoma (PHCC) respectively. In the control group, amplified HBV-DNA was detected in 25% of the subjects without HBsAg and anti-HBs antibodies, and in 6% of subjects positive for anti-HBs antibodies. This study confirmed the hypothesis that there is an etiologic link between HBV and PHCC in HBsAg-negative patients.
 ...
PMID:Detection of hepatitis B virus DNA by polymerase chain reaction in HBsAg negative Senegalese patients suffering from cirrhosis or primary liver cancer. 177 20

Researchers analyzed 1983 vital statistics for Taiwan using the life table analysis and calculating the potential years of life lost (PYLL) to identify life shortening features of several major causes of death and examine the preventability of premature mortality. Life expectancy for males was 69.9 years whereas for females it was 75.1 years. these corresponding life expectancies for Japan were 73.8 years and 79.6 years and 71.7 years and 78.7 years for the US. Between 1950-1983, life expectancy at birth in Taiwan increased 17.5 years for males and 19 years for females. In 1983, the cumulative total of PYLL before age 70 for males was 737,205 compared to 353,780 years for females. Thus loss of productivity of males was 2 times that of females. Most of this loss was a result of accidents. In fact, they contributed to 37.2% of PYLL for males and 24.9% of PYLL for females. Even though accidents were also the leading cause for the most PYLL in Japan and the US (17.4% and 8.7% respectively in Japan and 25% for both sexes combined in the US), the magnitude was considerably lower than that of Taiwan. Further the type of accidents males were more likely to die from were motor vehicle accidents (18,8% vs. 18.4% for home and workplace accidents). On the other hand, women were more likely to die from home and workplace accidents(14% vs. 10%). The 2nd major cause for the most PYLL was all cancers, except liver cancer, (15.9% for males and 20.4% for females). The 3rd major cause for the most PYLL for males was liver disease (liver cancer and cirrhosis of the liver) (9.6%) while for females it was stroke (8.7%). Further suicides contributed to 6.5% of PYLL for females. IN conclusion, Taiwan should place accident prevention as a high priority since it needs limited resources and is more achievable than that of cancer elimination. The next level of preventive efforts should include stroke and suicide.
 ...
PMID:Mortality trend in a rapidly developing economy in Taiwan. Part II: Life expectancy and "potential years of life lost". 179 32

The intravascular injection of the formerly used contrast medium Thorotrast--a colloidal suspension of thorium-dioxide--causes a chronic exposure to alpha-particles especially in the organs of the reticuloendothelial system. The German Thorotrast Study comprises 2326 Thorotrast patients and 1890 contemporary matched patients in the control group to be evaluated. 899 Thorotrast patients and 662 controls had clinical and biophysical follow-up examinations every two years since 1969. The recent most important results of the study are: A high excess rate of primary liver cancer (410/2) was observed beginning after the 15th year of exposure. 31% of the tumors are combined with cirrhosis and 6% with other neoplastic diseases. A clear (mean) dose rate effect relationship exists. The tumor frequency depends on the time of exposure or the cumulative dose to the liver respectively and not primarily on the age at injection. The lowest cumulative doses at 10 years before diagnosis of liver cancer were about 2 Gy. Risk estimates for liver cancer after 40 years of exposure are 500 malignant tumors per 10(4) person-Gy for men and 300 for women. A high excess rate exists also for leukaemias (excluding CLL) starting already 5 years after Thorotrast injection (39/4). The lowest cumulative doses to the red bone marrow at time of death were about 0.5 Gy. According to the present result, an excess rate can be expected for carcinomas of the extrahepatic bile ducts, pancreas, oesophagus, larynx, as well as Non-Hodgkin's lymphomas, bone sarcomas, plasmacytomas and mesotheliomas.
 ...
PMID:Neoplastic diseases induced by chronic alpha-irradiation--epidemiological, biophysical and clinical results of the German Thorotrast Study. 182 56


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>